SAN Sanofi

93.23USD84.82 EUR · EPA+1.23%Mkt Cap: 112.07B USDP/E: 24.54

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It …

Institutional holders15 on file

Key Statistics

Company
Market Cap112.07B USD
Enterprise Value127.67B USD
Revenue (TTM)56.04B USD
Gross Profit37.01B USD
Net Income (TTM)8.59B USD
Revenue/Share46.57 USD
Last Price93.23 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees74.8K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - General
ISINFR0000120578
Valuation
P/E (Trailing)24.54
P/E (Forward)8.91
PEG2.83
EV/EBITDA7.86
EV/Revenue2.28
P/S2.00
P/B1.40
EPS (TTM)3.80 USD
EPS (Forward)10.47 USD
52W Range
76.6778% of range97.83
52W High97.83 USD
52W Low76.67 USD
Profitability
Gross Margin72.07%
Oper. Margin22.28%
EBITDA Margin28.98%
Profit Margin16.72%
ROE10.95%
ROA6.16%
ROIC9.54%
ROCE9.75%
Growth
Revenue Growth15.70%
Earnings Growth9.40%
Cash Flow & Leverage
Operating CF11.82B USD
CapEx (TTM)3.89B USD
FCF Margin16.23%
FCF Yield8.12%
Net Debt15.26B USD
Net Debt/EBITDA0.94
Net Debt/FCF1.68
Balance Sheet
Debt/Equity0.28
Current Ratio1.12
Quick Ratio0.21
Book Value/Sh66.76 USD
Cash/Share5.47 USD
Dividends
Fwd Div Rate4.53 USD
Trail. Div Rate0.00 USD
Div. Yield4.78%
5Y Avg Yield4.03%
Payout Ratio119.08%
Ex-Div DateMay 5, 2026
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)105.92 USD
Upside (mean)+13.6%
Target Range86.84 USD – 120.91 USD
86.84+13.6% to mean120.91
# Analysts23
Ownership
Shares Out.1.20B
Float1.08B
Insiders10.31%
Institutions42.02%
Technical
SMA 5083.90 (+11.1%)
SMA 20084.64 (+10.1%)
Beta0.26
S&P 52W Chg8.68%
Avg Vol (30d)2.53M
Avg Vol (10d)2.57M
Technical Indicators
RSI (14)61.2
MACD2.9511
MACD Signal3.1840
MACD Hist.-0.2328
BB Upper101.26 USD
BB Middle91.21 USD
BB Lower81.15 USD
BB Width22.05%
ATR (14)2.025 USD
Vol Ratio (20d)1.02x

About Sanofi (EPA: SAN)

›

Sanofi (EPA: SAN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 74,846 employees.

The shares were at 84.82 EUR on 20 November 2026, down 1.2% over 52 weeks. Its 52-week range is 69.75 EUR to 89.00 EUR: the price is 4.7% below the high and 21.6% above the low.

At a market capitalisation of 101.96B EUR, it trades at 24.5 times trailing earnings and 8.9 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 26.1, so SAN is valued in line with them. It pays a dividend yielding 4.78% (it pays out 119% of its earnings), against a median of 2.45% among the dividend payers in that peer group.

Sanofi reports return on equity of 10.9%, an operating margin of 22.3% and revenue up 15.7% year over year.

Its debt exceeds its cash by 13.88B EUR, a debt-to-equity ratio of 0.28. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 96.36 EUR is 13.6% above the current price. The next earnings report is expected on 28 January 2027.